Novel Antibody Engineering Technology to Avoid On-Target Off-Tumour Reaction & Its Possible Application to ADC

Time: 11:00 am
day: Track A - Day 2 AM


  • Addressing on-target off-tumour toxicity; one of the common challenges in the field of therapeutic antibody
  • Demonstrating our unique antibody platform, Switch-Ig®, to avoid on-target off-tumour reaction by exploiting a unique property of tumour microenvironment
  • Switch-Ig® confers antibodies with additional tumour selectivity, which could maximise the therapeutic index of ADC